Publications by authors named "Nathan Demars"
Background: Veledimex (VDX)-regulatable interleukin-12 (IL-12) gene therapy in recurrent glioblastoma (rGBM) was reported to show tumor infiltration of CD8+ T cells, encouraging survival, but also up-regulation of immune checkpoint signaling, providing the rationale for a combination trial with immune checkpoint inhibition.
Methods: An open-label, multi-institutional, dose-escalation phase I trial in rGBM subjects (NCT03636477) accrued 21 subjects in 3 dose-escalating cohorts: (1) neoadjuvant then ongoing nivolumab (1mg/kg) and VDX (10 mg) (n = 3); (2) neoadjuvant then ongoing nivolumab (3 mg/kg) and VDX (10 mg) (n = 3); and (3) neoadjuvant then ongoing nivolumab (3 mg/kg) and VDX (20 mg) (n = 15). Nivolumab was administered 7 (±3) days before resection of the rGBM followed by peritumoral injection of IL-12 gene therapy.
Human interleukin-12 (hIL-12) is a cytokine with anticancer activity, but its systemic application is limited by toxic inflammatory responses. We assessed the safety and biological effects of an hIL-12 gene, transcriptionally regulated by an oral activator. A multicenter phase 1 dose-escalation trial (NCT02026271) treated 31 patients undergoing resection of recurrent high-grade glioma.
View Article and Find Full Text PDFArticle Synopsis
- Advances in cystic fibrosis (CF) treatment have complicated care regimens, creating challenges in self-management, especially for adolescents and their parents.
- The study involved interviews with 18 youth with CF and their parents to explore adherence barriers and facilitators related to daily treatment routines.
- Key barriers included time constraints and lack of perceived consequences for non-adherence, while facilitators involved understanding treatment importance, building relationships with care teams, and transitioning responsibilities from parents to adolescents.
Employment experiences among adolescents and young adults with cystic fibrosis.
Disabil Rehabil
August 2011
Purpose: We sought to examine the employment experiences in a population of adolescents and young adults with cystic fibrosis (CF).
Methods: We administered a cross-sectional survey to 68 individuals with CF, ages 16-25 years, assessing current employment experiences and perceptions of the impact of CF on these experiences.
Results: Forty-six percent of respondents reported working < 20 h per week.
Objective: The aim of this study was to develop the Transition Readiness Assessment Questionnaire (TRAQ), a measure of readiness for transition from pediatric to adult healthcare for youth with special health care needs (YSHCN).
Methods: We administered TRAQ to 192 YSHCN aged 16-26 years in three primary diagnostic categories, conducted factor analysis, and assessed differences in TRAQ scores by age, gender, race, and primary diagnosis type.
Results: Factor analysis identified two TRAQ domains with high internal consistency: Skills for Self-Management and Skills for Self-Advocacy.